- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02201979
Laser Fluorescent Imaging of Nipple and Areola During Breast Lift
Laser Fluorescent Imaging of Nipple and Areola During Breast Lift in Combination With Breast Implants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Protocol
Laser Fluorescent Imaging of Breasts During Vertical Breast Lifts and Reductions Performed in Combination with Breast Implants.
Background/Purpose
Today, breast lifts are a common operation. Implants may be recommended to provide greater fullness of the upper poles of the breasts. One of the risks of surgery is compromised circulation to the nipples and areolae. Some investigators believe that the simultaneous insertion of breast implants adds to the risk by causing pressure on the overlying breast tissue and skin.1 Staging the procedure (first the breast lift and then implants or vice versa) has been recommended, but staging is inconvenient and costly for patients, necessitating two operations. Clinical experience with the newer vertical breast lift technique, as opposed to the traditional inferior pedicle technique, has been favorable, with few reported complications.2 The vertical technique uses a shorter, more superficial pedicle than the traditional inferior pedicle, with a more reliable blood supply.2 A breast lift and reduction are essentially the same operation; more breast tissue is removed during a reduction but the dissection is the same.
This study was undertaken to investigate the blood supply to the nipples and areolae during the combined breast lift/reduction and implants procedure. Laser fluorescent imaging represents an objective measurement technique that has been used for several years to monitor the vascularity of flaps used in breast reconstruction.
Subjects
Fifteen consecutive consenting adult women undergoing outpatient elective breast lifts or reductions in combination with breast implants will be investigated. By testing the blood supply at two time points, the patient serves as her own control.
Imaging
The SPY Elite Intraoperative Perfusion Assessment System (Lifecell Corp., Branchburg, NJ) consists of a near-infrared laser that detects fluorescence. The imaging agent, indocyanine green, is absorbed at 800-810 nm. The imaging agent is injected intravenously. Starting within 5-10 seconds of injection, the system records images of the breasts, showing the fluorescence, which indicates blood supply. The half-life of the imaging agent is 2.5-3 minutes.
Surgery
The implants are inserted and the breast lift/reduction procedure is performed on both sides using the vertical technique.2 The implants are not inflated. The filling tubes are left in place. At this point, 3 mL (7.5 mg) of indocyanine green is injected and the image is recorded, documenting blood supply to both breasts. Next, the implants are inflated using the filling tubes. After inflation of the implants, the breasts are reimaged, with the filling tubes still in place. Once adequate circulation is demonstrated, the filling tubes are removed. In the unlikely event that inadequate circulation is found during imaging, the implant volume may be reduced accordingly, and a third image taken to confirm adequate circulation to the nipples.
Null Hypothesis
A breast lift or reduction performed using the vertical technique in combination with insertion of breast implants does not compromise circulation to the nipples and areolae and may be safely performed simultaneously, avoiding a need for staged surgery.
Informed Consent
Patients are informed as to the nature of the study and are told that their participation is entirely voluntary and they are free to decline, and that doing so does not in any way prejudice their treatment. Patients are informed of the small risk of an allergic reaction that will be treated if it occurs.
Patient Risk
There is no patient risk apart from a very small risk of allergic reaction, which is further reduced by excluding any patient with a known allergy to iodinated contrast dye. The study does not affect patient treatment. It offers the possibility of detection of reduced skin circulation, information that can be used by the surgeon to limit implant volume, or forego their simultaneous insertion if necessary and reduce the risk of tissue loss and delayed wound healing, known complications of breast lifts and reductions.
Sample Size
A sample of 15 patients is anticipated, treated over a period of approximately 5 months.
Disclosure
The author has no financial interest in any of the products, devices, or drugs mentioned in this article. The author has no conflicts of interest to disclose. There was no outside funding for this study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Kansas
-
Leawood, Kansas, United States, 66211
- Swanson Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women aged 18 - 80
- Consent for participation
Exclusion Criteria:
- history of allergy to iodinated contrast dye -
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Breast lift in combination with implants.
Patients undergoing breast lifts in combination with implants are studied using laser fluorescent imaging to evaluate blood supply.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood supply to breast as evaluated by laser fluorescent imaging
Time Frame: 5 months
|
Laser fluorescent imaging is used to evaluate breast blood supply.
|
5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric Swanson, M.D., Swanson Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Swanson 004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Sagging
-
Seoul National University HospitalCompletedSagging Eyelid Skin
-
ESM Technologies, LLCPrinceton Consumer Research CorporationEnrolling by invitation
-
University of Sistan and BaluchestanEnrolling by invitationLow Back Pain | Muscle Weakness | Breast SaggingIran
-
Therabody, Inc.Eurofins CRL Cosmetics, Inc.CompletedWrinkles | Contour | Fine Lines | Sagging Skin | Dark Spots | Firmness | Skin Tone | Radiance/LuminosityUnited States
-
Yonsei UniversityCompletedSkin Aging | Laxity; Skin | Sagging SkinSouth Korea
-
GC AestheticsRecruitingBreast Augmentation | Breast Reconstruction | Breast Reconstruction Following Mastectomy | Breast Reconstruction Surgery | Breast Implants | Breast Revision | Breast Reconstruction With Silicone Implants | Breast Reconstruction After MastectomyUnited Kingdom
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Sientra, Inc.Active, not recruitingBreast Augmentation | Breast Reconstruction | Breast RevisionUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseCompletedBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast CancerUnited States
Clinical Trials on Vertical breast lift with implants
-
Murat Kaan ErdemCompletedAnterior Open Bite | Skeletal Open Bite | Hyperdivergent Growth Pattern | Hyperdivergent Facial PatternTurkey
-
European Institute of OncologyCompletedBreast Reconstruction | Radiation Therapy Complication | Prepectoral Breast ReconstructionItaly
-
University in Zielona GóraConvaTec Inc.UnknownBreast Cancer | Breast ReconstructionPoland
-
Mentor Worldwide, LLCCompletedBreast Augmentation | Breast Reconstruction | Breast Revision
-
Motiva USA LLCActive, not recruitingBreast ImplantsUnited States, Sweden, Germany
-
Maastricht University Medical CenterWithdrawn
-
Mentor Worldwide, LLCActive, not recruitingPrimary Breast Augmentation | Primary Breast Reconstruction | Revision Breast Augmentation | Revision Breast ReconstructionUnited States
-
AllerganTerminatedBreast Augmentation | Breast Reconstruction | Breast Implant RevisionUnited States
-
Johnson & Johnson Medical (Shanghai) Ltd.RecruitingBreast Augmentation and Breast ReconstructionChina